Table 2:

Patient-level sensitivity or true positive rate (TPR) and screening test-level false positive rate (FPR) for detecting any stage HCC at published thresholds for 6, 12, and 24 months prior to HCC diagnosis and the associated 95% bootstrap percentile intervals.

	HCC within 6 months (HCC cases: 33, Non-HCC: 526)		HCC within 12 months (HCC cases: 42, Non-HCC: 517)		HCC within 24 months (HCC cases: 49 Non-HCC: 497)
	TPR (%)	FPR (%)	TPR (%)	FPR (%)	TPR (%)	FPR (%)
AFP>20 ng/mL	18.2 (6.2–32.1)	4.1 (2.8–5.5)	23.8 (11.4–37.5)	3.8 (2.6–5.2)	22.4 (11.4–34.1)	3.7 (2.5–5.1)
AFP-L3%>10%	33.3 (16.7–48.5)	5.5 (3.9–7.3)	35.7 (21.1–50.0)	5.2 (3.6–7.0)	32.7 (19.6–45.6)	5.0 (3.4–6.9)
DCP>7.5 ng/mL	15.2 (4.2–29.4)	1.4 (0.7–2.1)	11.9 (3.0–22.7)	1.4 (0.8–2.2)	12.2 (4.3–22.2)	1.3 (0.7–2.0)
AFP>20 ng/mL, AFP-L3%>10% or DCP>7.5 ng/mL	39.4 (23.3–56.2)	9.7 (7.8–11.9)	47.6 (31.9–62.8)	9.3 (7.4–11.3)	46.9 (32.6–60.3)	8.8 (6.8–10.9)
GALAD> −0.63	63.6 (46.9–78.8)	22.9 (19.8–26.5)	73.8 (60.0–86.4)	22.2 (19.1–25.8)	71.4 (58.8–83.3)	21.5 (18.5–25.1)
HES>10.17%	24.2 (10.0–40.0)	5.9 (4.3–7.8)	26.2 (12.8–39.6)	5.6 (4.0–7.5)	26.5 (14.0–39.1)	5.3 (3.7–7.1)